Wire · opportunities
The Emerging Role of Blood-Based Lung Cancer Screening
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 31 August 2026 · Fusion42 review
Freenome's SimpleScreen Lung test is an investigational blood-based lung cancer screening test granted FDA Breakthrough Device Designation, showing promising sensitivity and specificity but still requiring more clinical validation before approval. Oncology nurses play a key role in educating patients about the test's investigational status and the continued recommendation of low-dose CT scans.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Your lung cancer screening medtech product now faces rising pressure to integrate liquid biopsy with AI due to FDA's Breakthrough Device Designation for Freenome's blood test. You must clarify patient and clinician use cases to avoid confusion and maintain relevance while CT scan remains standard.
◆ Coverage
1 source · 31 Aug 2026
◆ Related on Wire
◆ Topics